Application and Effect
Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus.Linagliptin acts to lower blood glucose levels by inhibiting the enzyme DPP-4, thereby preventing the degradation of the incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic peptide) and attenuating postprandial glucose excursions.Product Sample
Product Packing:
Additional Information:
| Composition | C25H28N8O2 |
| Assay | 99% |
| Appearance | White powder |
| CAS No. | 668270-12-0 |
| Packing | 25KG |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |